Get all your news in one place.

100’s of premium titles.
One app.

Start reading

Get all your news in one place.

100’s of premium titles. One news app.

Start reading

The Latest Breaking News from Bharat Biotech

Public money, private patents? Unravelling India’s opacity over its Covid vaccines

Public money, private patents: Unravelling India’s opacity over its Covid vaccines

Newslaundry

Adolescent girls at risk after receiving Covaxin, says study

Adolescents and those with comorbidities face higher risks of adverse events post-Covaxin vaccination, as per recent study.

The Hindu

Covishield under scanner: Is Covaxin safe?

AstraZeneca's statement in court papers has sparked health concerns worldwide, especially in countries like India where COVISHIELD has been given to a large part of the population. The British pharmaceutical giant has admitted that its COVID vaccine can lead to a rare side effect called TTS or Thrombosis with Thrombocytopenia…

The Times of India

From analysis to the latest developments in health,
read the most diverse news in one place.

"Safety is primary focus for all our vaccines": Covaxin-developer Bharat Biotech amid reports on AstraZeneca vaccine

Amid reports over potential rare side effects of the AstraZeneca-Oxford COVID-19 vaccine, Bharat Biotech, which developed the Covaxin, said in a statement that the vaccine was developed with a "single-minded focus on safety first." Read further on Dynamite News:

Dynamite News

Clinical trials of Spanish tuberculosis vaccine MTBVAC begin in India

Clinical trials of MTBVAC, a genetically modified TB vaccine, have begun in India by Bharat Biotech and Biofabri.

The Hindu

India-made typhoid vaccine efficacy lasts for four years: study

A phase-3 trial in Malawi shows that Bharat Biotech's typhoid vaccine provides lasting efficacy for at least four years in children aged nine months to 12 years.

The Hindu

Bharat Biotech, University of Sydney sign MoU for vaccine research

Bharat Biotech and Sydney ID sign MoU to advance vaccine research, strengthen academic-industry partnerships and tackle infectious diseases. Aims to leverage strengths of both to develop safer vaccine platforms and make lasting impact on global health. CEPI-funded AVAR-T programme to develop SARS-CoV-2 vaccine also part of collaboration.

The Hindu

Read news from The Economist, FT, and more,
with one subscription

‘Defence-aerospace focus should be on anti-drone tech especially after Russia-Ukraine war’

Hyderabad hosts close to 1,000 micro, small and medium scale industries involved in the defence and aerospace sector. TS Special Secretary-Invest E. Vishu Vardhan Reddy said the Russia-Ukraine war has shown the need to focus on anti-drone technology. Former DRDO chairman G. Satheesh Reddy said industry needs assured supply orders,…

The Hindu

Businessline Millets Conclave: Krishna Ella calls for GST waiver for millets

The Hindu

The case for India switching from the oral to the inactivated polio vaccine

No matter the polio status of a country and which vaccine is being used, as long as wild poliovirus is present and any country continues to use the oral polio vaccine (OPV), the risk of polio emergence, including in polio-free countries, is real in a globalised village especially when vaccine…

The Hindu

Hyderabad-based Bharat Biotech recalls typhoid vaccine batch owing to substandard quality

It added that the recall was initiated utilising the principle of abundant precaution based on test results of field samples by the Central Drugs Laboratory.

The Hindu

Behind the ‘dearth’ of rabies vaccine in India

A lack of forecasting and irregular demand by States, as well poor coordination has resulted in a shortage of anti-rabies vaccine

The Hindu

Govt. approves India's first nasal vaccine: Know how a nasal vaccine works

The union government has approved Bharat Biotech's intranasal vaccine, iNCOVACC. It will be used as a heterologous booster will be available first in private hospitals. It will be included in COVID vaccination program from today, official sources have told the media.

The Times of India

Covid infection could be lowered with unique intranasal vaccine

The sprays have been found to stop the virus from attaching itself to cells in the nose, reducing the likelihood of an infection.

Evening Standard

Get all your
news in one place.

100’s of premium titles.
One news app.

The Independent UK

India and China clear needle-free COVID-19 vaccines

India and China have cleared two needle-free options for COVID-19 vaccinations

The Hindu

Bharat Biotech’s intra-nasal COVID vaccine gets emergency use approval

This is India’s first intra-nasal vaccine for COVID-19

Dynamite News

COVID-19: India's first intranasal vaccine by Bharat Biotech gets DCGI approval

The Bharat Biotech on Tuesday got emergency use authorisation from the Drugs Controller General of India (DCGI) for the Intranasal Covid-19 vaccine. Read more on Dynamite News:

The Times of India

Coronavirus: Bharat Biotech's nasal vaccine cleared for use, tweets health minister

Homegrown nasal vaccine, manufactured by Bharat Biotech, has been cleared for use. In a series of tweets, Union Health Minister Dr Mansukh Mandaviya, has confirmed the approval of the nasal vaccine.

Get all your
news in one place.

100’s of premium titles.
One news app.

The Hindu

Nigeria deploys Bharat Biotech’s Rotavac to protect children

Rotavirus oral vaccine used to immunise against life-threatening diarrhoeal disease

The Hindu

Clinical trials of intranasal COVID vaccine over; data submitted to regulators

Bharat Biotech says BBV154 found to be safe, well-tolerated, immunogenic

Reuters

Exclusive-Rotavirus childhood vaccine shortage hits four African countries

Supplies of a vaccine to prevent the deadly rotavirus infection in children have either run out in Kenya, Tanzania, Senegal and Cameroon or are close to doing so, officials close to the roll-out told Reuters, after disruptions at drugmaker GSK.

The Hindu

Bharat Biotech expects regulator’s nod for intranasal COVID-19 vaccine this month

Bharat Biotech completed clinical trials of the nasal vaccine with about 4,000 volunteers and there is no side effect or adverse reaction reported so far

The Times of India

Covaxin booster safe, fights SARS-CoV-2 sub-variants: Nature

HYDERABAD: A third dose of Bharat Biotech’s Covid-19 vaccine, Covaxin, is safe and increases the concentration of neutralising antibodies against the ancestral vaccinated individuals, according to the results of a study published in reputed scientific journal Nature.

Benzinga

Ocugen's Partner COVID-19 Vaccine Covaxin Shows Encouraging Action In Children Below 18 Years

Ocugen Inc (NASDAQ:OCGN) announced the publication of positive pediatric Phase 2/3 study results in children aged 2–18 years for COVID-19 vaccine, Covaxin (BBV152), in The Lancet Infectious Diseases. Covaxin is developed and manufactured by Ocugen's India-based partner Bharat Biotech International Limited. It is under clinical investigation by Ocugen in the U.S. for use…

The Hindu

Covaxin demonstrates robust safety and immunogenicity in children 2-18 years: Bharat Biotech

A total of 374 adverse events were reported and majority of them were mild in nature and resolved within a day, said the company

1 2 3

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Washington University

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.